Previous studies have linked plasma inflammatory markers to elevated fatigue in patients with head and neck cancer (HNC). To identify the molecular mechanisms underlying this association, we conducted promoter-based bioinformatics analyses to determine the relationship between fatigue and specific gene expression profiles associated with inflammation in human papillomavirus (HPV)-related and -unrelated HNC patients undergoing treatment. Patients with newly diagnosed HNC without distant metastasis were assessed at baseline (pre-radiotherapy) and one-month post-radiotherapy. Fatigue was measured by the Multidimensional Fatigue Inventory. Genome-wide gene expression profiles were collected from peripheral blood mononuclear cells (PBMC). Promoter-based bioinformatics analyses were employed to identify transcription control pathways underlying transcriptomic correlates of fatigue in the sample as a whole and in HPV-related and HPV-unrelated HNC patients separately. In transcriptome profiling analyses of PBMC from 44 patients, TELiS bioinformatics analyses linked fatigue to increased nuclear factorkappa B (NF-kB) transcriptional activity and decreased interferon regulatory factor family (IRF) transcription factor activity. Patients with HPV-related HNC showed lower levels of fatigue-related gene expression profile compared to HPV-unrelated HNC. Fatigue in HNC patients undergoing treatment is associated with gene expression profiles consistent with the conserved transcriptional response to adversity (CTRA) characterized by increased proinflammatory and decreased antiantiviral transcriptional activity. Interestingly, this CTRA response was mitigated in patients with HPV-related HNC and may explain the lower level of fatigue they experience relative to HPV-unrelated HNC.
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Fatigue, one of the most frequently reported and distressing cancer symptoms (Janaki et al., 2010) , is prognostic for poor pathologic tumor response (Park et al., 2009) and survival (Ackerstaff et al., 2012; Fang et al., 2004; Montazeri, 2009) , including in patients with head and neck cancer (HNC) (Ackerstaff et al., 2012; Fang et al., 2004) . Indeed, an increase in baseline fatigue of 10 points (out of 100) is associated with a 17% reduction in survival in HNC patients (Fang et al., 2004) . A rise in the incidence of HNC, due to the increased incidence of human papillomavirus (HPV) infection, has been noted, and by 2020 HPV-positive HNCs will likely be the most common HPV-associated cancer in the US (Chaturvedi et al., 2011) . HNC patients typically receive radiotherapy (RT) and experience high rates of fatigue compared to other cancer patients (Hickok et al., 2005) . Most commonly used intensitymodulated RT (IMRT), targeting tumors with higher doses while avoiding normal structures, causes even higher fatigue compared to conventional RT for HNC (Gulliford et al., 2012) . Our previous work in HNC patients has shown that RT-induced fatigue is consistently ranked among the top three most common and severe symptoms and is significantly related to multiple other treatment-related symptoms (e.g. mucositis and dry mouth) (Xiao et al., 2013) . However, the management of fatigue is challenging, and no Food and Drug Administration (FDA)-approved pharmacological agent reliably prevents or treats this symptom (Minton et al., 2010) . Understanding the biological mechanisms of cancer-related fatigue may help improve the management of this distressing symptom.
One biological mechanism that may contribute to fatigue is systemic inflammation. Our previous work has identified a positive association between fatigue and peripheral inflammatory cytokines and their receptors in HNC patients. This association exists not only before and during the acute phase of cancer treatment (within one-month of the completion of radiotherapy or concurrent chemoradiotherapy) (Xiao et al., 2016) , but also at three-month after completion of cancer treatment (Xiao et al., 2018) . 
